Vyome Holdings, Inc.
- HIND
- NASDAQ
- Biotechnology
- Clinical-Stage Biotech
- Immuno-Inflammatory Therapeutics
$1.86
Today +1.09%Quote Oct 20, 2026, 02:09 PM UTC
−12.38%over the last month
Max drawdown −12.4%From 1-month high −12.4%3 months −15.6%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Vyome
Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disorders. Founded in 2017, the company extends its market reach throughout the United States and into global territories, headquartered in Princeton, New Jersey.
Where the money comes from
Q2 2026 revenue $58,546
- Product$50,28585.9%
- Royalty$8,26114.1%
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
18
Founded
2017
Market value
$13.1M
Quote Oct 20
Analyst target
$3.50
+88.2% from here
Floor
$1.82
2.2% below price
Resistance
$1.93
3.8% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about HINDPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free